InflaRx N.V. 9,411,765 Ordinary Shares Underwriting AgreementUnderwriting Agreement • April 13th, 2023 • InflaRx N.V. • Pharmaceutical preparations • New York
InflaRx N.V., a public limited liability company (naamloze vennootschap) under Dutch law, (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 9,411,765 ordinary shares, nominal value €0.12 per share (the “Ordinary Shares”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,411,764 Ordinary Shares of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are referred to herein as the “Securities”. The Ordinary Shares to be outstanding after giving effect to the sale of the Securities are referred to herein as the “Stock”. To the extent there are no additional Underwriters listed on Schedule 1 other than you, the term “Representative” as used herein shall mean you, as Underwriter, and the terms “Representative” and “Underwriter” shall mean either the singula
InflaRx N.V. Ordinary Shares (nominal value €0.12 per share) SALES AGREEMENTSales Agreement • June 28th, 2024 • InflaRx N.V. • Pharmaceutical preparations • New York
InflaRx N.V., a public limited liability company (naamloze vennootschap) under Dutch law (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:
InflaRx N.V. [3,000,000] Common Shares Underwriting AgreementUnderwriting Agreement • May 2nd, 2018 • InflaRx N.V. • Pharmaceutical preparations • New York
InflaRx N.V., a public limited liability company (naamloze vennootschap) under Dutch law, (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [1,500,000] common shares with a nominal value of €0.12 per share in the capital of the Company (the “Common Shares”) and certain shareholders of the Company named in Schedule 2 hereto (the “Selling Shareholders”) propose to sell to the several Underwriters an aggregate of [1,500,000] Common Shares of the Company (collectively, the “Underwritten Shares”). In addition, the Company proposes to issue and sell, at the option of the Underwriters, up to an additional [350,000] Common Shares of the Company and the Selling Shareholders propose to sell, at the option of the Underwriters, up to an additional [100,000] Common Shares of the Company (collectively, the “Option Shares”). The Underwritten Share
FORM OF INDEMNIFICATION AGREEMENTIndemnification Agreement • October 13th, 2017 • Fireman B.V. • Pharmaceutical preparations
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [ ] between InflaRx N.V., a public company with limited liability (naamloze vennootschap) incorporated under the laws of the Netherlands (the “Company”), and [ ] (“Indemnitee”).
Co-Development AgreementCo-Development Agreement • November 7th, 2017 • Fireman B.V. • Pharmaceutical preparations
efforts of the Parties and set the rules and conditions for such co-development as in principle set forth above (hereinafter also referred to as the “Purpose” of this Agreement).
MÜNCHENLease Agreement • October 13th, 2017 • Fireman B.V. • Pharmaceutical preparations
English Summary of a lease agreement dated April 10, 2017 (the Lease) by and between the Immoprojekt Grundstücksverwaltungsgesellschaft mbh (the Landlord) and InflaRx GmbH (the Tenant)
REGISTRATION RIGHTS AGREEMENT dated as of November [●], 2017 among INFLARX N.V. and THE SHAREHOLDERS PARTY HERETORegistration Rights Agreement • October 26th, 2017 • Fireman B.V. • Pharmaceutical preparations • New York
THIS REGISTRATION RIGHTS AGREEMENT dated as of November [●], 2017 (this “Agreement”) by and among InflaRx N.V., a Dutch public company with limited liability (the “Company”), and the shareholders listed on the signature pages hereto, as well as any Permitted Transferees (as defined below).
SHARE PURCHASE AGREEMENTShare Purchase Agreement • December 21st, 2022 • InflaRx N.V. • Pharmaceutical preparations • New York
THIS SHARE PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of December 21, 2022 between InflaRx N.V., a public limited liability company (naamloze vennootschap) organized under Dutch law (the “Company”), and Staidson Hong Kong Investment Company Limited, a limited liability company organized under the law of Hong Kong (the “Purchaser”). The Company and the Purchaser are referred to herein each as a “Party” and together as the “Parties.”
REGISTRATION RIGHTS AGREEMENT dated as of November 7, 2017 among INFLARX N.V. and THE SHAREHOLDERS PARTY HERETORegistration Rights Agreement • November 9th, 2017 • InflaRx N.V. • Pharmaceutical preparations • New York
NOTARIAL DEED INVESTMENT AND SHAREHOLDERS’ AGREEMENT Series C Preferred Shares Financing InflaRx GmbH, Jena, GermanyInvestment and Shareholders’ Agreement • October 13th, 2017 • Fireman B.V. • Pharmaceutical preparations
InflaRx GmbH with its registered seat at Jena and with business Address at DE 07745 Jena, Winzerlaer Strasse 2, registered with the commercial register at the local court of Jena under HRB 502149,
